Her2 in brain metastases: Issues of concordance, survival, and treatment [9]

Journal of Clinical Oncology

Volumn 20, Issue 19, 2002, Pages 4130-4133

  Fuchs, Ilka B ^a   Loebbecke, Maren ^a   Buhler, Helmut ^a   Stoltenburg Didinger, Gisela ^a   Heine, Bernhard ^a   Lichtenegger, Werner ^a   Schaller, Gerard ^a   Charite, C Virchow ^a  

^a Universitäts Frauenklinik   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; TRASTUZUMAB;

ADULT; BLOOD BRAIN BARRIER; BRAIN METASTASIS; BRAIN RADIATION; BREAST CANCER; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG PENETRATION; DRUG RESPONSE; FEMALE; GENE AMPLIFICATION; HUMAN; IMMUNOHISTOCHEMISTRY; LETTER; MALE; METASTASIS; ONCOGENE NEU; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR BIOPSY;

EID: 0036788636     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.04.016     Document Type: Letter

References (11)

1. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001
2. Vogel CL, Cobleigh MA, Tripathy D, et al: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719-726, 2002
3. Pestalozzi BC, Brignoli S: Trastuzumab in CSF. J Clin Oncol 18:2350-2351, 2000
4. Baculi RH, Suki S, Nisbett, J, et al: Meningeal carcinomatosis from breast carcinoma responsive to trastuzumab. J Clin Oncol 19:3297-3298, 2001
5. Kallioniemi OP, Holli K, Visakorpi T, et al: Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer 49:650-655, 1991
6. Lower EE, Blau R, Bismayer J, et al: Increased brain metastasis detected in metastatic breast cancer patients receiving herceptin, Breast Cancer Res Treat 69:271, 2001 (abstr 357)
7. Boettcher B, Kahlert S, Bauerfeind I, et al: Loss of HER-2-overexpression during herceptin therapy in metastatic breast cancer. Breast Cancer Res Treat 64:109, 2001 (abstr 454)
8. Edgerton SM, Merkel DE, More DH, et al: HER-2/neu/ErbB-2 status by immunohistochemistry and FISH: Clonality and progression with recurrence and metastases. Breast Cancer Res Treat 64:55, 2001 (abstr 180)
9. Ishida H, Sadahiro S, Suzuki T, et al: C-erbB-2 protein expression and clinicopathologic features in colorectal cancer. Oncol Rep 7: 1229-1233, 2000
10. Jimenez RE, Hussain M, Bianco FJ Jr, et al: Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: Prognostic significance and comparative analysis in primary and metastatic tumors. Clin Cancer Res 7:2440-2447, 2001
11. Akatsuka T, Wada T, Kokai Y, et al: Loss of ErbB2 expression in pulmonary metastatic lesion in osteosarcoma. Oncology 60:361-366, 2001